Figure 6 | Scientific Reports

Figure 6

From: FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis

Figure 6

Hepatic NF-κB pathway activity in prophylactic and therapeutic study groups.

(A) TransAM® assay showing decreased p65 activation indicative of NF-κB pathway activity following OCA treatment in the therapeutic study arm. (B) IκBα is increased significantly after OCA administration in the prophylactic study arm. NF-κB, nuclear transcription factor-kappa beta; TAA, thioacetamide; OCA, obeticholic acid; IκBα, nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha.

Back to article page